Technological requirements for adaptation

Article

Is it possible to adapt current femtosecond lasers to perform cataract surgery?

"There are five femtosecond laser systems on the market that perform their job pretty well in corneal surgery. They are femtosecond lasers, their interaction is based on photodisprution and they cut the cornea," he continued. "Recently we have had another group of femtosecond lasers become available that also perform photodisruption of the eye, however, these do not do it on the cornea but on the lens."

Looking into these systems further and trying to answer the question of adaptability, Prof. Lubatschowski examined the technological similarities and differences of the lasers.

"A similarity between these lasers is the photodisruption process," Prof. Lubatschowski said. Both use femtosecond pulse duration for this process, which is beneficial for precision - short pulses allow for higher precision. Using these femtosecond pulses in the range of nanoJoule to microJoule energy allows the lasers to reach the intensity threshold required to disrupt the relevant tissue without too large cavitation bubbles being formed and with much more control.

Additionally, the wavelength of the lasers are the same. "1000 nm is at least the cheapest wavelength available to produce femtosecond pulses and that's why all these lasers have wavelengths in that range, which is capable of penetrating the eye," he added.

Application of the lasers is a further similarity, with both requiring eye fixation and the patient-laser interface either being matched by moving the patient bed or the laser mirror arm of the system.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.